Current immunotherapeutic strategies encompass adoptive T‐cell therapy, engineered TCR T‐cells, and PD‐1 and CTLA‐4 checkpoint blockade for cervical cancer intervention. The gene discussed is PDCD1; the disease is cervical cancer.